- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05550948
Uso da fotobiomodulação transcraniana para melhorar a cognição e resultados auto-relatados em sobreviventes de câncer infantil
Survivors of childhood cancer are at greater risk for long-term cognitive impairments that include attention, executive function, intelligence, memory, and processing speed. The participants are a survivor of acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma (HL). Because of your treatment the participant may have developed trouble with thinking and learning.
Primary Objective
To evaluate the feasibility of using home-based tPBM paired with remote cognitive training to improve cognitive performance in survivors of ALL and HL.
Secondary Objectives
To estimate the potential efficacy of alpha and gamma frequency tPBM on cognitive performance in survivors of ALL and HL.
Exploratory Objectives
To estimate the effects of home-based tPBM paired with remote cognitive training on patient reported symptoms of executive dysfunction, sleep, depression, anxiety, fatigue, and pain in survivors of ALL and HL.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Survivors with ALL and HL with identified executive function impairment will be randomized to receive stimulation with alpha tPBM + cognitive training, gamma tPBM + cognitive training or sham tPBM + cognitive training three days per week for a 2-month intervention period The tPBM will be applied to nodes in the default mode network.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38105
- St. Jude Children's Research Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Completed treatment for acute lymphoblastic leukemia (ALL) or Hodgkin's Lymphoma (HL) at SJCRH.
- Enrolled in SJLIFE, and less than 21 years of age at diagnosis.
- 18 years of age or older at time of enrollment.
- 2 years or greater post-treatment completion of cancer directed therapy and not currently receiving any cancer directed therapy.
- English language proficiency.
- Access to WiFi.
- Executive dysfunction defined as having an age-adjusted standard score less than 16th percentile on objectively assessed cognitive test or patient-reported executive dysfunction defined as having a standard score greater than 84th percentile within 3 years of time of enrollment.
Exclusion Criteria:
- Estimated intelligence score less than 80.
- Currently taking medication intended to treat neurocognitive impairment (i.e., stimulants).
- Major psychiatric condition.
- Alcohol abuse in the past year (AUDIT) [greater than or equal to 13 for women and greater than or equal to 15 for men]. The Alcohol Use Disorders Identification Test (AUDIT) will be used to screen for individuals who have active alcohol-use disorders.
- Drug abuse in the past year (DAST-10) [ greater than or equal to 3 for women or men] The Drug Abuse Screen Test (DAST-10) will be used to screen for individuals with active drug abuse.
- History of neurologic condition or genetic disorder associated with neurocognitive impairment unrelated to cancer diagnosis or treatment.
- Enrolled on another independent cognitive intervention protocol within the last year.
- Female participants who are pregnant or lactating (determined by participant self-report due to the remote nature of this study)
- Tattoo or artificial marking in the area where the device will be positioned.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Viabilidade do dispositivo
- Alocação: Randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: alpha tPBM + cognitive training
three days per week for a 2-month intervention period (5 ALL and 5 HL) |
The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
Outros nomes:
|
|
Experimental: gamma tPBM + cognitive training
three days per week for a 2-month intervention period (5 ALL and 5 HL) |
The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
Outros nomes:
|
|
Experimental: sham tPBM + cognitive training
Sham stimulations will act as the control for this study three days per week for a 2-month intervention period (5 ALL and 5 HL) |
The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants who completed a two-month trial of paired photobiomodulation (PBM) therapy and cognitive training
Prazo: 4 months after participant enrollment
|
The trial will be considered feasible if at least 15 of 30 survivors are able to complete 18 of 24 sessions (PBM along with cognitive training). |
4 months after participant enrollment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
CNS Vital Signs adaptions of the Rey auditory verbal learning test (RVLT).
Prazo: 2 month and 4 months after enrollment
|
RVLT is a test that evaluate working memory. |
2 month and 4 months after enrollment
|
|
CNS Vital Signs adaptions of the Rey visual design learning (RVDL) test.
Prazo: 2 month and 4 months after enrollment
|
RVDL is a test that evaluate working memory. |
2 month and 4 months after enrollment
|
|
CNS Vital Signs implemented Stroop color and word test.
Prazo: 2 month and 4 months after enrollment
|
The Stroop test is a test that evaluates Inhibitory control. |
2 month and 4 months after enrollment
|
|
CNS Vital Signs implemented Shifting Attention Test.
Prazo: 2 month and 4 months after enrollment
|
The Shifting attention test and Stroop test are tests that are used to measure cognitive flexibility. |
2 month and 4 months after enrollment
|
|
CNS Vital Signs implementation of the Continuous Performance Test (CPT).
Prazo: 2 month and 4 months after enrollment
|
The CPT test is a test that evaluates attention. |
2 month and 4 months after enrollment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Nicholas Phillips, MD,PhD, St. Jude Children's Research Hospital
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PBMP
- NCI-2022-09116 (Outro identificador: NCI Clinical Trial Registration Program)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .